AEST.MED.INT.HLD.SP.ADR/3 (3FMA) — Net Asset Quality Index
AEST.MED.INT.HLD.SP.ADR/3 (3FMA) has a Net Asset Quality Index of -8.5% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €510.89 Million minus total liabilities of €554.12 Million yields net assets of €-43.23 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read AEST.MED.INT.HLD.SP.ADR/3 (3FMA) financial obligations for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
AEST.MED.INT.HLD.SP.ADR/3 Net Asset Quality Index Over Time (2021–2025)
This chart shows how AEST.MED.INT.HLD.SP.ADR/3's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the index stands at -8.5%, representing net assets of €-43.23 Million against total assets of €510.89 Million EUR. For live market cap and overall valuation, see market cap of AEST.MED.INT.HLD.SP.ADR/3.
Annual Net Asset Quality Index for AEST.MED.INT.HLD.SP.ADR/3 (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for AEST.MED.INT.HLD.SP.ADR/3 from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check 3FMA capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -8.5% | €-43.23 Million | €510.89 Million | €554.12 Million | ▼ -10.4 pp |
| 2024 | 1.9% | €9.35 Million | €486.22 Million | €476.88 Million | ▼ -4.1 pp |
| 2023 | 6.0% | €33.63 Million | €560.66 Million | €527.03 Million | ▲ +29.0 pp |
| 2022 | -23.0% | €-125.88 Million | €546.37 Million | €672.25 Million | ▲ +9.3 pp |
| 2021 | -32.3% | €-186.42 Million | €576.94 Million | €763.36 Million | — |